SCHEMBL6685331

SCHEMBL6685331

CC(O)(CC(N)=O)N(CCC(=O)O)S(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 5/20 0.48
LTA4H P09960 2/20 0.45
MMP13 P45452 4/20 0.42
MMP2 P08253 3/20 0.42
MMP9 P14780 2/20 0.42
FFAR1 O14842 1/20 0.42
NR3C1 P04150 1/20 0.39
SOS1 Q07889 1/20 0.39
MEP1B Q16820 1/20 0.39
SCN9A Q15858 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
CETP P11597 1/20 0.37
MMP8 P22894 1/20 0.37
MMP14 P50281 1/20 0.37
MMP16 P51512 1/20 0.37
MMP7 P09237 1/20 0.37
RAB9A P51151 1/20 0.37
CACNA1H O95180 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7421019 0.88 SMN1; SMN2 (0.46) MMP1LTA4HMMP13MMP2MMP9
SCHEMBL231737 0.81 MMP1 (0.55) MMP1LTA4HMMP13MMP2MMP9
SCHEMBL6809658 0.70 MMP13 (0.50) MMP1LTA4HMMP13MMP2MMP9
SCHEMBL7344819 0.70 MMP1 (0.43) MMP1MMP13MMP2MMP9MEP1B
SCHEMBL6817940 0.70 MMP1 (0.48) MMP1MMP13MMP2MMP9NR3C1
SCHEMBL27839121 0.69 MMP1 (0.64) MMP1LTA4HMMP13MMP2MMP9
SCHEMBL27856906 0.69 MMP1 (0.67) MMP1LTA4HMMP13MMP2MMP9
SCHEMBL1133869 0.69 MMP8 (0.65) MMP1MMP13MMP2MMP9FFAR1
SCHEMBL5243658 0.68 MMP1 (0.56) MMP1LTA4HMMP13MMP2MMP9
SCHEMBL6903460 0.68 MMP1 (0.53) MMP1LTA4HMMP13MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1003720-B1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PROD INC (US) 2004-03-31 EP claimed
US-6214872-B1 ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS PFIZER INC. 2001-04-10 US claimed
EP-1003720-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Pfizer Products Inc. (US) 2000-05-31 EP claimed
WO-1999007675-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-02-18 WO claimed
EP-3137460-A1 CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES Pfizer Inc. (US) 2017-03-08 EP disclosed
WO-2015166373-A1 CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES PFIZER INC. (US) 2015-11-05 WO disclosed
CN-102807617-A Antibodies to M-CSF WARNER LAMBERT CO 2012-12-05 CN disclosed
CN-1835975-B Modified human IGF-1R antibodies PFIZER PROD INC 2012-11-21 CN disclosed
CN-101128484-B Compositions comprising anti-IGF-1 receptor antibodies and methods for obtaining same AMGEN INC 2012-09-26 CN disclosed
CN-1863817-B Antibodies to M-CSF WARNER LAMBERT CO 2012-07-04 CN disclosed
CN-101018780-B Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors PFIZER 2012-01-11 CN disclosed
WO-2004083248-A9 ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS PHARMACIA CORP (US) 2004-12-29 WO disclosed
EP-1415984-A1 Aryloxyarylsulfonylamino hydroxamic acid derivatives Pfizer Products Inc. (US) 2004-05-06 EP disclosed
EP-1003720-B1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PROD INC (US) 2004-03-31 EP disclosed
US-6214872-B1 ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS PFIZER INC. 2001-04-10 US disclosed
EP-1003720-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Pfizer Products Inc. (US) 2000-05-31 EP disclosed
WO-1999007675-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-02-18 WO disclosed